Table 5.
Composition of the N-glycan structures in Varlilumab co-expressed with chimeric β1,3β1,4-GALT in N. benthamiana.
| Abbreviation | Structure | N-glycopeptide ratio (%) |
|---|---|---|
| M3XF | Man3XylFuc | 4.1 |
| GNM2XF | GlcNAcMan2XylFuc | 4.6 |
| GNXF | GlcNAcMan3XylFuc | 12.4 |
| GN2X | GlcNAc2Man3Xyl | 4.8 |
| GN2XF | GlcNAc2Man3XylFuc | 41.5 |
| Gal2(β1,4)GN2XF | Gal2GlcNAc2Man3XylFuc | 4.4 |
| M6 | Man6 | 7.2 |
| M7 | Man7 | 5.8 |
| M8 | Man8 | 7.8 |
| M9 | Man9 | 7.3 |
| Total | 100 | |
|
Terminal β1,4-Gal residue
β1,2-Xylosylated and α1,3-Fucosylated Oligomannosidic structure Lewis a structure β1,2-Xylosylated |
4.4 67.0 20.8 - 4.8 |
|